Sunshine Biopharma Inc., a pharmaceutical company focused on the research, development, and commercialization of drugs for the treatment of various forms of cancer, has formed an agreement with Lonza for the manufacture of its anti-cancer small-molecule drug, Adva-27a. Manufacturing will begin at Lonza's Nansha, China facility with the remaining key steps to be conducted in Lonza's high-containment cytotoxic facility in Visp, Switzerland.

Adva-27a is Sunshine Biopharma’s lead anticancer compound, a topoisomerase II inhibitor, small molecule that has recently been shown to be effective at killing multidrug-resistant breast cancer cells, small-cell lung cancer cells, uterine sarcoma cells, and pancreatic cancer cells. The company is planning separate Phase I clinical trials for treating multidrug-resistant breast cancer and pancreatic cancer.

Source: Sunshine Biopharma